HRP20180098T1 - Kombinacije koje obuhvaćaju brekspiprazol ili jednu njegovu sol i jedan drugi lijek za uporabu u liječenju cns-poremećaja - Google Patents
Kombinacije koje obuhvaćaju brekspiprazol ili jednu njegovu sol i jedan drugi lijek za uporabu u liječenju cns-poremećaja Download PDFInfo
- Publication number
- HRP20180098T1 HRP20180098T1 HRP20180098TT HRP20180098T HRP20180098T1 HR P20180098 T1 HRP20180098 T1 HR P20180098T1 HR P20180098T T HRP20180098T T HR P20180098TT HR P20180098 T HRP20180098 T HR P20180098T HR P20180098 T1 HRP20180098 T1 HR P20180098T1
- Authority
- HR
- Croatia
- Prior art keywords
- disorder
- treatment
- cognitive impairment
- anhedonia
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (12)
1. Medikament, naznačen time, da obuhvaća sljedeće:
(I) spoj koji je 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoksi]-1H-kinolin-2-on ili jedna njegova sol, i
(II) najmanje jedan lijek odabran iz skupine koja se sastoji od inhibitora povratne apsorpcije serotonina, i inhibitora povratne apsorpcije serotonina i noradrenalina;
pri čemu se kod navedenog inhibitora povratne apsorpcije serotonina radi o najmanje jednom lijeku odabranom iz skupine koju čine fluoksetin, citalopram, fluvoksamin, paroksetin, sertralin, escitalopram i njihove soli, a
kod navedenog inhibitora povratne apsorpcije serotonina i noradrenalina, radi se o najmanje jednom lijeku odabranom iz skupine koju čine venlafaksin, duloksetin, milnacipran, desvenlafaksin i njihove soli.
2. Medikament prema zahtjevu 1, naznačen time, da medikament obuhvaća navedeni spoj (I) i navedeni lijek (II) u jedinstvenom pripravku.
3. Medikament prema zahtjevu 1, naznačen time, da medikament obuhvaća jedan sastav koji obuhvaća navedeni spoj (I) i jedan sastav koji obuhvaća navedeni lijek (II), koji su formulirani odvojeno, te se sastav od navedenog spoja (I) pripravlja za uporabu u kombinaciji sa sastavom od navedenog lijeka (II).
4. Medikament prema bilo kojem od zahtjeva 1 do 3, naznačen time, da se kod navedenog lijeka (II) radi o inhibitoru povratne apsorpcije serotonina, koji je najmanje jedan lijek odabaran iz skupine koju čine fluoksetin, citalopram, fluvoksamin, paroksetin, sertralin, escitalopram i njihove soli.
5. Medikament prema bilo kojem od zahtjeva 1 do 3, naznačen time, da se kod navedenog lijeka (II) radi o inhibitoru povratne apsorpcije serotonina i noradrenalina, koji je najmanje jedan lijek odabaran iz skupine koju čine venlafaksin, duloksetin, milnacipran, desvenlafaksin i njihove soli.
6. Medikament prema bilo kojem od zahtjeva 1 do 5, naznačen time, da se upotrebljava u profilaksi ili liječenju bolesti centralnog neurološkog sustava.
7. Medikament za uporabu prema zahtjevu 6, naznačen time, da se kod bolesti centralnog neurološkog sustava radi o bolesti centralnog neurološkog sustava odabranoj iz skupine koju čine: shizofrenija, otpornost na liječenje, uporna ili kronična shizofrenija, emocionalne povrede, psihotički poremećaj, poremećaj raspoloženja, bipolarni poremećaj (primjerice bipolarni poremećaj tipa I i bipolarni poremećaj tipa II), manija, depresija, endogena depresija, jaka depresija, melankolija i depresija otporna na liječenje, distimija, ciklotimijski poremećaj, anksioznost (primjerice napadi panike, panični poremećaj, agorafobija, socijalna fobija, opsesivno-kompulzivni poremećaj, post-traumatski stresni poremećaj, generalizirana anksioznost, akutni stresni poremećaj), somatoformni poremećaj (primjerice histerija, somatizacijski poremećaj, konverzijski poremećaj, poremećaj s bolovima, hipohondrija), fiktivni poremećaj, disocijativni poremećaj, seksualni poremećaj, (primjerice seksualna disfunkcija, poremećaj seksualne želje, poremećaj seksualne napetosti, erektilna disfunkcija), poremećaj hranjenja (primjerice anoreksija, bulimija) poremećaj spavanja, poremećaj prilagodbe, poremećaj povezan sa supstancom (primjerice zlouporaba alkohola, trovanje alkoholom i ovisnost o drogi, trovanje stimulansom, narkotizam), anhedonija (primjerice iatrogenska anhedonija, anhedonija s psihičkim ili mentalnim uzrokom, anhedonija povezana s depresijom, anhedonija povezana sa shizofrenijom), delirij, kognitivno oštećenje, kognitivno oštećenje povezano s Alzheimerovom, Parkinsonovom te ostalim neurodegenerativnim bolestima, kognitivno oštećenje uzrokovano Alzheimerovom bolešću, Parkinsonovom bolešću i s time povezanim neurodegenerativnim bolestima, kognitivno oštećenje kod shizofrenije, kognitivno oštećenje uzrokovano otpornošću na liječenje, uporna ili kronična shizofrenija, povraćanje, bolest kretanja/putovanja, pretilost, migrena, bol, mentalna retardacija, autistični poremećaj (autizam), Touretteov sindrom, poremećaj s tikovima, poremećaj hiperaktivnosti s pomanjkanjem pažnje, ozbiljan poremećaj vladanja i Downov sindrom.
8. Farmaceutski sastav, naznačen time, da obuhvaća medikament prema bilo kojem od zahtjeva 1 do 5 te najmanje jedan farmakološki prihvatljiv nosač.
9. Medikament, naznačen time, da on obuhvaća (I) spoj koji je 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoksi]-1H-kinolin-2-on ili jedna njegova sol, za primjenu u liječenju bolesti centralnog neurološkog sustava kod pacijenta kojemu se daje (II) najmanje jedan lijek odabran iz skupine koja se sastoji od inhibitora povratne apsorpcije serotonina i inhibitora povratne apsorpcije serotonina i noradrenalina;
pri čemu je navedeni inhibitor povratne apsorpcije serotonina najmanje jedan lijek odabaran iz skupine koju čine fluoksetin, citalopram, fluvoksamin, paroksetin, sertralin, escitalopram i njihove soli, dok je navedeni inhibitor povratne apsorpcije serotonina i noradrenalina najmanje jedan lijek odabran iz skupine koju čine venlafaksin, duloksetin, milnacipran, desvenlafaksin i njihove soli.
10. Medikament za uporabu prema zahtjevu 9, naznačen time, da se kod liječenja radi o liječenju bolesti centralnog neurološkog sustava koja je odabrana iz skupine koju čine: shizofrenija, otpornost na liječenje, uporna ili kronična shizofrenija, emocionalne povrede, psihotički poremećaj, poremećaj raspoloženja, bipolarni poremećaj (primjerice bipolarni poremećaj tipa I i bipolarni poremećaj tipa II), manija, depresija, endogena depresija, jaka depresija, melankolija i depresija otporna na liječenje, distimija, ciklotimijski poremećaj, anksioznost (primjerice napadi panike, panični poremećaj, agorafobija, socijalna fobija, opsesivno-kompulzivni poremećaj, post-traumatski stresni poremećaj, generalizirana anksioznost, akutni stresni poremećaj), somatoformni poremećaj (primjerice histerija, somatizacijski poremećaj, konverzijski poremećaj, poremećaj s bolovima, hipohondrija), fiktivni poremećaj, disocijativni poremećaj, seksualni poremećaj, (primjerice seksualna disfunkcija, poremećaj seksualne želje, poremećaj seksualne napetosti, erektilna disfunkcija), poremećaj hranjenja (primjerice anoreksija, bulimija) poremećaj spavanja, poremećaj prilagodbe, poremećaj povezan sa supstancom (primjerice zlouporaba alkohola, trovanje alkoholom i ovisnost o drogi, trovanje stimulansom, narkotizam), anhedonija (primjerice iatrogenska anhedonija, anhedonija s psihičkim ili mentalnim uzrokom, anhedonija povezana s depresijom, anhedonija povezana sa shizofrenijom), delirij, kognitivno oštećenje, kognitivno oštećenje povezano s Alzheimerovom, Parkinsonovom te ostalim neurodegenerativnim bolestima, kognitivno oštećenje uzrokovano Alzheimerovom bolešću, Parkinsonovom bolešću i s time povezanim neurodegenerativnim bolestima, kognitivno oštećenje kod shizofrenije, kognitivno oštećenje uzrokovano otpornošću na liječenje, uporna ili kronična shizofrenija, povraćanje, bolest kretanja/putovanja, pretilost, migrena, bol, mentalna retardacija, autistični poremećaj (autizam), Touretteov sindrom, poremećaj s tikovima, poremećaj hiperaktivnosti s pomanjkanjem pažnje, ozbiljan poremećaj vladanja i Downov sindrom.
11. Medikament, naznačen time, da on obuhvaća (II) najmanje jedan lijek odabran iz skupine koja se sastoji od inhibitora povratne apsorpcije serotonina i inhibitora povratne apsorpcije serotonina i noradrenalina, za primjenu u liječenju bolesti centralnog neurološkog sustava kod pacijenta kojemu se daje (I) spoj koji je 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoksi]-1H-kinolin-2-on ili jedna njegova sol;
pri čemu je navedeni inhibitor povratne apsorpcije serotonina najmanje jedan lijek odabaran iz skupine koju čine fluoksetin, citalopram, fluvoksamin, paroksetin, sertralin, escitalopram i njihove soli, dok je navedeni inhibitor povratne apsorpcije serotonina i noradrenalina najmanje jedan lijek odabran iz skupine koju čine venlafaksin, duloksetin, milnacipran, desvenlafaksin i njihove soli.
12. Medikament za uporabu prema zahtjevu 11, naznačen time, da se kod liječenja radi o liječenju bolesti centralnog neurološkog sustava koja je odabrana iz skupine koju čine: shizofrenija, otpornost na liječenje, uporna ili kronična shizofrenija, emocionalne povrede, psihotički poremećaj, poremećaj raspoloženja, bipolarni poremećaj (primjerice bipolarni poremećaj tipa I i bipolarni poremećaj tipa II), manija, depresija, endogena depresija, jaka depresija, melankolija i depresija otporna na liječenje, distimija, ciklotimijski poremećaj, anksioznost (primjerice napadi panike, panični poremećaj, agorafobija, socijalna fobija, opsesivno-kompulzivni poremećaj, post-traumatski stresni poremećaj, generalizirana anksioznost, akutni stresni poremećaj), somatoformni poremećaj (primjerice histerija, somatizacijski poremećaj, konverzijski poremećaj, poremećaj s bolovima, hipohondrija), fiktivni poremećaj, disocijativni poremećaj, seksualni poremećaj, (primjerice seksualna disfunkcija, poremećaj seksualne želje, poremećaj seksualne napetosti, erektilna disfunkcija), poremećaj hranjenja (primjerice anoreksija, bulimija) poremećaj spavanja, poremećaj prilagodbe, poremećaj povezan sa supstancom (primjerice zlouporaba alkohola, trovanje alkoholom i ovisnost o drogi, trovanje stimulansom, narkotizam), anhedonija (primjerice iatrogenska anhedonija, anhedonija s psihičkim ili mentalnim uzrokom, anhedonija povezana s depresijom, anhedonija povezana sa shizofrenijom), delirij, kognitivno oštećenje, kognitivno oštećenje povezano s Alzheimerovom, Parkinsonovom te ostalim neurodegenerativnim bolestima, kognitivno oštećenje uzrokovano Alzheimerovom bolešću, Parkinsonovom bolešću i s time povezanim neurodegenerativnim bolestima, kognitivno oštećenje kod shizofrenije, kognitivno oštećenje uzrokovano otpornošću na liječenje, uporna ili kronična shizofrenija, povraćanje, bolest kretanja/putovanja, pretilost, migrena, bol, mentalna retardacija, autistični poremećaj (autizam), Touretteov sindrom, poremećaj s tikovima, poremećaj hiperaktivnosti s pomanjkanjem pažnje, ozbiljan poremećaj vladanja i Downov sindrom.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161471911P | 2011-04-05 | 2011-04-05 | |
| US201161580540P | 2011-12-27 | 2011-12-27 | |
| EP12719460.3A EP2694043B1 (en) | 2011-04-05 | 2012-04-04 | Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder |
| PCT/JP2012/059825 WO2012137971A1 (en) | 2011-04-05 | 2012-04-04 | Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180098T1 true HRP20180098T1 (hr) | 2018-03-23 |
Family
ID=46045045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180098TT HRP20180098T1 (hr) | 2011-04-05 | 2012-04-04 | Kombinacije koje obuhvaćaju brekspiprazol ili jednu njegovu sol i jedan drugi lijek za uporabu u liječenju cns-poremećaja |
Country Status (33)
| Country | Link |
|---|---|
| US (7) | US20140120185A1 (hr) |
| EP (5) | EP2694043B1 (hr) |
| JP (2) | JP5992924B2 (hr) |
| KR (1) | KR101890450B1 (hr) |
| CN (2) | CN103547260B (hr) |
| AR (1) | AR085840A1 (hr) |
| AU (1) | AU2012240864B2 (hr) |
| BR (1) | BR112013025420B1 (hr) |
| CA (1) | CA2832157C (hr) |
| CO (1) | CO6801769A2 (hr) |
| CY (1) | CY1120567T1 (hr) |
| DK (1) | DK2694043T3 (hr) |
| EA (1) | EA035837B1 (hr) |
| ES (1) | ES2654851T3 (hr) |
| HK (1) | HK1246159A1 (hr) |
| HR (1) | HRP20180098T1 (hr) |
| HU (1) | HUE035542T2 (hr) |
| IL (1) | IL228669B (hr) |
| JO (2) | JOP20120083B1 (hr) |
| LT (1) | LT2694043T (hr) |
| MX (2) | MX390286B (hr) |
| MY (1) | MY166936A (hr) |
| NZ (1) | NZ615591A (hr) |
| PH (3) | PH12020500280A1 (hr) |
| PL (1) | PL2694043T3 (hr) |
| PT (1) | PT2694043T (hr) |
| RS (1) | RS56802B1 (hr) |
| SG (2) | SG193468A1 (hr) |
| SI (1) | SI2694043T1 (hr) |
| SM (1) | SMT201800033T1 (hr) |
| TW (1) | TWI636784B (hr) |
| WO (1) | WO2012137971A1 (hr) |
| ZA (1) | ZA201306981B (hr) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3753B1 (ar) * | 2011-10-14 | 2021-01-31 | Otsuka Pharma Co Ltd | قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه |
| TWI632921B (zh) * | 2011-10-19 | 2018-08-21 | 大塚製藥股份有限公司 | 口服溶液 |
| TW201332572A (zh) * | 2011-12-28 | 2013-08-16 | Otsuka Pharma Co Ltd | 具有經取代的β－環糊精之藥物製劑 |
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| JOP20210047A1 (ar) * | 2012-10-25 | 2017-06-16 | Otsuka Pharma Co Ltd | عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه |
| WO2014144663A1 (en) * | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| MX2016013889A (es) | 2014-04-22 | 2017-03-09 | Otsuka Pharma Co Ltd | Medicamento. |
| WO2015188092A1 (en) * | 2014-06-06 | 2015-12-10 | Rhodes Pharmaceuticals, L.P. | Methods for treating attention deficit hyperactivity disorder with methylphenidate |
| CA2902911C (en) | 2014-10-31 | 2017-06-27 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| CA3019351C (en) | 2016-04-01 | 2023-09-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Regulatory device and associated method |
| US11123300B2 (en) | 2016-08-16 | 2021-09-21 | Hexal Ag | Immediate release tablet of a benzothiophene compound |
| WO2018033484A1 (en) | 2016-08-16 | 2018-02-22 | Hexal Aktiengesellschaft | Pharmaceutical compositions of a benzothiophene compound |
| PT3532064T (pt) * | 2016-10-28 | 2020-09-03 | H Lundbeck As | Tratamentos de combinação compreendendo imidazopirazinonas para o tratamento de distúrbios psiquiátricos e/ou cognitivos |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| EP3501506B1 (en) * | 2017-12-19 | 2019-10-09 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising brexpiprazole |
| JP2019183095A (ja) * | 2018-08-16 | 2019-10-24 | 株式会社Ｄｎｐファインケミカル | 接着性粉体、接着性錠剤の製造方法、接着性錠剤、並びに該接着性粉体及び錠剤を用いた部材又は部品の製造方法 |
| JP6831354B2 (ja) * | 2018-08-16 | 2021-02-17 | 株式会社Ｄｎｐファインケミカル | 接着性組成物からなる錠剤、その製造方法、及び該錠剤を用いた部材又は部品の製造方法 |
| CN112805306B (zh) * | 2018-10-04 | 2024-05-14 | 洛桑联邦理工学院(Epfl) | 可交联聚合物、水凝胶及其制备方法 |
| CA3117169A1 (en) * | 2018-10-24 | 2020-04-30 | Effector Therapeutics, Inc. | Crystalline forms of mnk inhibitors |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
| JP2022529353A (ja) | 2019-04-17 | 2022-06-21 | コンパス パスファインダー リミテッド | 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法 |
| JPWO2021029020A1 (hr) * | 2019-08-13 | 2021-02-18 | ||
| US11229644B1 (en) * | 2020-12-31 | 2022-01-25 | Lake O'hara Llc | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
| CN113322299A (zh) * | 2021-05-28 | 2021-08-31 | 南昌大学 | 一种抑郁症和药物成瘾疾病的药物靶点识别方法 |
| CN116407539B (zh) * | 2021-12-30 | 2025-01-10 | 上海现代药物制剂工程研究中心有限公司 | 依匹哌唑甲基脂肪酸酯的用途 |
| US20240009181A1 (en) * | 2022-07-08 | 2024-01-11 | Jason Eric Schiffman | Method for the treatment and prophylaxis of substance-related and/or addictive disorders including substance/medication-induced depressive disorders, bipolar and related disorders, and anxiety disorders and compositions useful for the same |
| FR3142667A1 (fr) * | 2022-12-01 | 2024-06-07 | Capsum | Composition solide non pulvérulente comprenant au moins 8% en poids d’agent(s) désintégrant |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
| TR2023018024A1 (tr) * | 2023-12-22 | 2025-07-21 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Brekspi̇prazol i̇çeren tabletler |
| TR2023018022A1 (tr) * | 2023-12-22 | 2025-07-21 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Brekspi̇prazol i̇çeren bi̇r tablet |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5178878A (en) | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
| IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
| TW587938B (en) * | 1997-03-27 | 2004-05-21 | Akzo Nobel Nv | Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder |
| US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| US20040176466A1 (en) * | 2001-08-08 | 2004-09-09 | Allen Albert John | Combination therapy for the treatment of neurological disorders |
| RU2356554C2 (ru) * | 2002-12-27 | 2009-05-27 | Оцука Фармасьютикал Ко., Лтд. | Производные карбостирила и ингибиторы обратного захвата серотонина для лечения эмоциональных расстройств |
| WO2006004719A2 (en) * | 2004-06-25 | 2006-01-12 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia |
| TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| JP4315393B2 (ja) * | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
| JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
| ES2354319T3 (es) * | 2006-10-27 | 2011-03-14 | Janssen Pharmaceutica, N.V. | Procedimientos para el tratamiento de trastornos de comportamiento disruptivo. |
| JP2008189616A (ja) * | 2007-02-07 | 2008-08-21 | Mitsubishi Tanabe Pharma Corp | 注意欠陥多動性障害の治療薬 |
| JP2011136906A (ja) * | 2008-04-18 | 2011-07-14 | Otsuka Pharmaceut Co Ltd | 複素環化合物 |
-
2012
- 2012-04-03 TW TW101111875A patent/TWI636784B/zh active
- 2012-04-03 AR ARP120101135A patent/AR085840A1/es unknown
- 2012-04-03 JO JOP/2012/0083A patent/JOP20120083B1/ar active
- 2012-04-04 AU AU2012240864A patent/AU2012240864B2/en active Active
- 2012-04-04 EP EP12719460.3A patent/EP2694043B1/en not_active Revoked
- 2012-04-04 CN CN201280017329.8A patent/CN103547260B/zh active Active
- 2012-04-04 WO PCT/JP2012/059825 patent/WO2012137971A1/en not_active Ceased
- 2012-04-04 JP JP2013546481A patent/JP5992924B2/ja active Active
- 2012-04-04 BR BR112013025420-3A patent/BR112013025420B1/pt active IP Right Grant
- 2012-04-04 CN CN201810096214.1A patent/CN108042808B/zh active Active
- 2012-04-04 MY MYPI2013701740A patent/MY166936A/en unknown
- 2012-04-04 EP EP22155365.4A patent/EP4023223A1/en not_active Withdrawn
- 2012-04-04 MX MX2019015237A patent/MX390286B/es unknown
- 2012-04-04 PL PL12719460T patent/PL2694043T3/pl unknown
- 2012-04-04 CA CA2832157A patent/CA2832157C/en active Active
- 2012-04-04 SG SG2013069273A patent/SG193468A1/en unknown
- 2012-04-04 NZ NZ615591A patent/NZ615591A/en unknown
- 2012-04-04 SM SM20180033T patent/SMT201800033T1/it unknown
- 2012-04-04 PT PT127194603T patent/PT2694043T/pt unknown
- 2012-04-04 US US14/009,436 patent/US20140120185A1/en not_active Abandoned
- 2012-04-04 EP EP17198877.7A patent/EP3299018A1/en not_active Withdrawn
- 2012-04-04 PH PH1/2020/500280A patent/PH12020500280A1/en unknown
- 2012-04-04 SG SG10201602326RA patent/SG10201602326RA/en unknown
- 2012-04-04 DK DK12719460.3T patent/DK2694043T3/en active
- 2012-04-04 SI SI201231192T patent/SI2694043T1/en unknown
- 2012-04-04 MX MX2013010796A patent/MX370670B/es active IP Right Grant
- 2012-04-04 RS RS20180064A patent/RS56802B1/sr unknown
- 2012-04-04 ES ES12719460.3T patent/ES2654851T3/es active Active
- 2012-04-04 EP EP25173601.3A patent/EP4570250A3/en active Pending
- 2012-04-04 LT LTEP12719460.3T patent/LT2694043T/lt unknown
- 2012-04-04 HR HRP20180098TT patent/HRP20180098T1/hr unknown
- 2012-04-04 PH PH1/2013/501908A patent/PH12013501908A1/en unknown
- 2012-04-04 KR KR1020137029250A patent/KR101890450B1/ko active Active
- 2012-04-04 PH PH1/2020/552079A patent/PH12020552079A1/en unknown
- 2012-04-04 EP EP19205895.6A patent/EP3626243A1/en not_active Withdrawn
- 2012-04-04 HU HUE12719460A patent/HUE035542T2/hu unknown
- 2012-04-04 EA EA201391450A patent/EA035837B1/ru not_active IP Right Cessation
-
2013
- 2013-09-17 ZA ZA2013/06981A patent/ZA201306981B/en unknown
- 2013-10-01 IL IL228669A patent/IL228669B/en active IP Right Grant
- 2013-11-05 CO CO13261085A patent/CO6801769A2/es not_active Application Discontinuation
-
2014
- 2014-05-09 HK HK18105601.0A patent/HK1246159A1/en unknown
-
2016
- 2016-08-18 JP JP2016160872A patent/JP2017031155A/ja active Pending
- 2016-12-21 US US15/386,289 patent/US20170100395A1/en not_active Abandoned
-
2017
- 2017-10-19 US US15/788,102 patent/US20180042923A1/en not_active Abandoned
-
2018
- 2018-01-17 CY CY20181100057T patent/CY1120567T1/el unknown
- 2018-07-20 US US16/041,246 patent/US20180325894A1/en not_active Abandoned
-
2021
- 2021-02-25 JO JOP/2021/0035A patent/JOP20210035A1/ar unknown
- 2021-03-10 US US17/197,725 patent/US20220000861A1/en not_active Abandoned
-
2023
- 2023-08-25 US US18/455,757 patent/US20240156811A1/en not_active Abandoned
-
2024
- 2024-10-07 US US18/907,757 patent/US20250177385A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180098T1 (hr) | Kombinacije koje obuhvaćaju brekspiprazol ili jednu njegovu sol i jedan drugi lijek za uporabu u liječenju cns-poremećaja | |
| AR059183A1 (es) | Uso de derivados de 2- imidazol o imidazolina sustituidos para preparar medicamentos | |
| RU2011113443A (ru) | Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов | |
| RU2011120816A (ru) | Производные индола и бензоксазина в качестве модуляторов метаботропных глутаматных рецепторов | |
| WO2008108517A3 (en) | Piperazinyl-propyl-pyrazole derivatives as dopamine d4 receptor antagonists, and pharmaceutical compositions containing the same | |
| JP2015521642A5 (hr) | ||
| JP2022180531A5 (hr) | ||
| Freire et al. | New treatment options for panic disorder: clinical trials from 2000 to 2010 | |
| MX2010009643A (es) | Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a). | |
| Lee et al. | Umbelliferone modulates depression-like symptoms by altering monoamines in a rat post-traumatic stress disorder model | |
| Pandi-Perumal et al. | The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives | |
| Casucci et al. | Therapeutic strategies in migraine patients with mood and anxiety disorders: physiopathological basis | |
| NO20061167L (no) | Kombinasjonen av en serotonin-reopptaksinhibitor og en glysintransporter type 1-inhibitor for behandling av depresjon | |
| BRPI0407247A (pt) | Derivados de 2,3-benzodiazepina substituìdos | |
| Seehusen et al. | Second-generation antidepressants for depression in adults | |
| AR048134A1 (es) | La combinacion de un inhibidor de la recaptacion de serotonina y un antagonista del receptor de la histamina 3, el agonista inverso o el agonista parcial | |
| Zhao et al. | Ketamine and its enantiomers in treatment-resistant depression: promise, pitfalls, and personalized psychiatry | |
| UA113846C2 (xx) | Медикамент, що містить брекспіпразол або його сіль та другий лікарський засіб, для використання у лікуванні розладу цнс | |
| EA201070736A1 (ru) | 4-[2,3-дифтор-6-(2-фтор-4-метилфенилсульфанил)фенил]пиперидин | |
| Noel et al. | The pharmacological management of stress reactions | |
| Miljatovic | P-1354-Comparative effects of venlafaxine and mirtazapine on sleep physiology measures in patients with major depresive disorder and insomnia | |
| Kotlyar et al. | Selective Serotonin Reuptake Inhibitors (SSRIs) | |
| US20060217394A1 (en) | Treatment of anhedonia | |
| Hamon | C. 15.02 Pharmacological profile of antidepressants: a likely basis for their efficacy and side effects? | |
| Souza-Marques et al. | Repurposed Drugs of Abuse (Stimulants, Ketamine, and Psychedelics): Focus on Risks |